Skip to main content

NEW YORK (TheDeal) -- Israeli drug company Teva Pharmaceutical Industries (TEVA) - Get Teva Pharmaceutical Industries Limited Sponsored ADR Report added to Merger Monday by saying it will buy Auspex Pharmaceuticals (ASPX) for $3.2 billion.

The deal will give Teva access to a pipeline of potential treatments of movement disorders such as Tourette syndrome and Huntington's chorea, as well as strengthening its wider central nervous system portfolio. Auspex' deutetrabenazine product, or SD-809, has been granted orphan drug designation for the treatment of Huntington's disease in the United States and could be approved for commercial launch as early as next year.

Earlier Monday UnitedHealth Group (UNH) - Get UnitedHealth Group Incorporated Report announced the $12.8 billion acquisition of pharmacy benefit management services provider Catamaran while Hyperion Therapeutics (HPTX)  is being bought for $1.1 billion by Horizon Pharma (HZNP) - Get Horizon Therapeutics Public Limited Company Report.

Other drugs in the Auspex pipeline include versions of drugs for pulmonary fibrosis and Parkinson's disease using Auspex's technology based on the hydrogen isotope deuterium, which it hopes can be used to modify dosages and reduce the toxicity of existing treatments. Deuterium is not radioactive but its best known use is in slowing the uranium fission process in nuclear reactors.

"We believe that the application of Auspex's deuterium platform to known pharmaceuticals holds great promise across a wide spectrum of neurological diseases and associated movement disorders," said Michael Hayden, Teva's president of Global R&D and chief scientific officer, in a statement.

TheStreet Recommends

Teva will offer Auspex shareholders $101 a share in cash, representing a total consideration of about $3.2 billion in enterprise value and $3.5 billion in equity value. It said it hopes to acquire all remaining shares not tendered under the original offer through a second-step merger at the same price. The transaction is expected to close in the middle of this year.

Teva has been combining its traditional generics business with innovative therapies, said the two companies fit strategically and the acquisition would both strengthen its core central nervous system business and expand its presence into underserved movement disorder markets, and the tics associated with Tourette among others.

It said the deal would enhance its mid- to long-term revenue and earnings growth, profitability and product diversity and was expected to be accretive to non-GAAP earnings per share beginning in 2017.

Read more from:

Image placeholder title